Kyocera (KYO) Forms $68.58 Double Top; Asterias Biotherapeutics (NYSEAMERICAN:AST) SI Decreased By 2.64%

Asterias Biotherapeutics Incorporated (NYSEAMERICAN:AST) had a decrease of 2.64% in short interest. AST’s SI was 2.51 million shares in January as released by FINRA. Its down 2.64% from 2.58M shares previously. With 89,700 avg volume, 28 days are for Asterias Biotherapeutics Incorporated (NYSEAMERICAN:AST)’s short sellers to cover AST’s short positions. The stock decreased 2.13% or $0.05 during the last trading session, reaching $2.3. About 496,152 shares traded or 168.20% up from the average. Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) has risen 4.43% since January 29, 2017 and is uptrending. It has underperformed by 12.27% the S&P500.

Kyocera Corporation (KYO) formed double top with $74.75 target or 9.00% above today’s $68.58 share price. Kyocera Corporation (KYO) has $24.63 billion valuation. The stock increased 0.75% or $0.51 during the last trading session, reaching $68.58. About 6,933 shares traded. Kyocera Corporation (NYSE:KYO) has risen 19.39% since January 29, 2017 and is uptrending. It has outperformed by 2.69% the S&P500.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $124.55 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: